1. Market Research
  2. > Vecta Ltd. - Product Pipeline Review - 2013

Vecta Ltd. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 24 pages

Vecta Ltd. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Vecta Ltd. - Product Pipeline Review - 2013” provides data on the Vecta Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vecta Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Vecta Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Vecta Ltd. - Brief Vecta Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Vecta Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Vecta Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Vecta Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Vecta Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Vecta Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Vecta Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Vecta Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Vecta Ltd. and identify potential opportunities in those areas.

Table Of Contents

Vecta Ltd. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Vecta Ltd. Snapshot 4
Vecta Ltd. Overview 4
Key Information 4
Key Facts 4
Vecta Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
Vecta Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Combination Treatment Modalities 9
Vecta Ltd. - Pipeline Products Glance 10
Vecta Ltd. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Vecta Ltd. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Vecta Ltd. - Drug Profiles 14
(Vecam + amoxicillin) 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
AVEC 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
PIVEC 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Vecam 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Vecta Ltd. - Pipeline Analysis 18
Vecta Ltd. - Pipeline Products by Therapeutic Class 18
Vecta Ltd. - Pipeline Products By Target 19
Vecta Ltd. - Pipeline Products by Route of Administration 20
Vecta Ltd. - Pipeline Products By Mechanism of Action 21
Vecta Ltd. - Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables

Vecta Ltd., Key Information 4
Vecta Ltd., Key Facts 4
Vecta Ltd. - Pipeline by Indication, 2013 6
Vecta Ltd. - Pipeline by Stage of Development, 2013 7
Vecta Ltd. - Monotherapy Products in Pipeline, 2013 8
Vecta Ltd. - Combination Treatment Modalities in Pipeline, 2013 9
Vecta Ltd. - Phase II, 2013 10
Vecta Ltd. - Phase I, 2013 11
Vecta Ltd. - Preclinical, 2013 12
Vecta Ltd. - Discovery, 2013 13
Vecta Ltd. - Pipeline By Therapeutic Class, 2013 18
Vecta Ltd. - Pipeline By Target, 2013 19
Vecta Ltd. - Pipeline By Route of Administration, 2013 20
Vecta Ltd. - Pipeline Products By Mechanism of Action, 2013 21

List of Figures

Vecta Ltd. - Pipeline by Indication, 2013 6
Vecta Ltd. - Pipeline by Stage of Development, 2013 7
Vecta Ltd. - Monotherapy Products in Pipeline, 2013 8
Vecta Ltd. - Combination Treatment Modalities in Pipeline, 2013 9
Vecta Ltd. - Pipeline By Therapeutic Class, 2013 18
Vecta Ltd. - Pipeline Products By Mechanism of Action, 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.